Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 11;16(20):3447.
doi: 10.3390/cancers16203447.

PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience

Ruoyu Miao  1 , Kirsten Blue  1 , Katelyn Sommerer  1 , Anand Shah  1 , Sal Bottiglieri  1 , Alex Del Cueto  2 , Darcy K Berry  2 , Teresa T Ho  2 , James Kevin Hicks  2 , Dae Won Kim  1
Affiliations

PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience

Ruoyu Miao et al. Cancers (Basel). .

Abstract

Background: Limited data are available regarding the anticancer activity of PARP inhibitors (PARPis) in pancreatic cancer with mutations in HRR genes other than BRCA and PALB2.

Methods: We retrospectively reviewed the clinical characteristics and outcomes of 48 patients with advanced pancreatic cancer harboring pathogenic germline and/or somatic HRR mutations who were treated with PARPis.

Results: Thirty patients had germline (g)HRR mutations only, twelve had somatic (s)HRR mutations only, and six had concomitant gHRR and sHRR mutations. The objective response rate (ORR) was 22%. The median progression-free survival (mPFS) and overall survival (mOS) were 6.9 and 11.5 months, respectively. Five patients received olaparib in the front-line setting due to borderline performance status. Their ORR was 20%, and their mPFS and mOS were both 11.3 months. The ORR was higher in patients with BRCA or PALB2 mutations (germline or somatic) than in those with non-BRCA/PALB2 mutations. Patients with somatic non-BRCA/PALB2 variants had a shorter mPFS. Patients with concomitant gHRR/sHRR mutations or gHRR mutations alone had a significantly longer mPFS than those with sHRR mutations only.

Conclusions: PARP inhibitors may be considered for patients with advanced pancreatic cancer harboring pathogenic alterations of BRCA who cannot tolerate standard chemotherapy. Maintenance PARPis can be considered in selected patients with non-BRCA/non-PALB2 HRR mutations.

Keywords: homologous recombination repair; pancreatic cancer; poly (ADP-ribose) polymerase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Kaplan–Meier curves of progression-free survival and overall survival stratified by germline vs. somatic mutation (A,B), HRR genes (C,D), and treatment setting (E,F).
See this image and copyright information in PMC

References

    1. Zheng F., Zhang Y., Chen S., Weng X., Rao Y., Fang H. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed. Pharmacother. 2020;123:109661. doi: 10.1016/j.biopha.2019.109661. - DOI - PubMed
    1. Das P.K., Matada G.S.P., Pal R., Maji L., Dhiwar P.S., Manjushree B.V., Viji M. Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship. Eur. J. Med. Chem. 2024;274:116535. doi: 10.1016/j.ejmech.2024.116535. - DOI - PubMed
    1. Mateo J., Lord C.J., Serra V., Tutt A., Balmaña J., Castroviejo-Bermejo M., Cruz C., Oaknin A., Kaye S.B., de Bono J.S. A decade of clinical development of PARP inhibitors in perspective. Ann. Oncol. 2019;30:1437–1447. doi: 10.1093/annonc/mdz192. - DOI - PMC - PubMed
    1. Lord C.J., Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355:1152–1158. doi: 10.1126/science.aam7344. - DOI - PMC - PubMed
    1. Park W., Chen J., Chou J.F., Varghese A.M., Yu K.H., Wong W., Capanu M., Balachandran V., McIntyre C.A., El Dika I., et al. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clin. Cancer Res. 2020;26:3239–3247. doi: 10.1158/1078-0432.CCR-20-0418. - DOI - PMC - PubMed

LinkOut - more resources